Synopsys at $460: Appealing Ahead of Dec. 8 Earnings

Synopsys (SNPS) trades at $459.95, down 9.81% in a month. Q3 revenue hit $2.48B, up 42.4%, with non-GAAP EPS of $3.91. Management raised full-year guidance to $15.07 EPS. Analysts revised fiscal 2027 EPS upwards. Debt and amortization concerns persist. Analysts see 28% upside with a target of $589.55. SNPS is down 2.08% YTD but up 14.77% over one year.

Original reporting
Published Nov 11, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 5:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Synopsys at $460: Appealing Ahead of Dec. 8 Earnings — source image
Decision brief

The 30-second read

$SNPSNeutralLow
01

Why it matters

The piece provides analysis but no new data, limiting trading relevance.

02

Market read

Recap of already‑public earnings; minimal trading value.

03

What to watch

Potential upside from upcoming Ansys integration progress not reflected in current price.

Relevance 4/10Novelty 2/10Timing: pre-market today

Background

Synopsys' Q3 performance and FY guidance were released on Aug 26, 2026; the article repeats those numbers without new developments.

Company-level read

Ticker impact

$SNPSNeutralHigh confidence
Context

Article recaps Q3 results and guidance that were released over two months ago, offering no new corporate event.

Expected impact

limited movement as market has already priced guidance.

Evidence & confidence

All figures quoted were previously disclosed; no new information to shift valuation.

Market effects

No immediate impact on the broader EDA sector.

None

None

Counterpoint

If investors believe the market has over‑discounted SNPS debt risk, a modest upside could emerge.

Key entities

  • Synopsys

    EDA and silicon IP provider.

Related articles

$SNPSMed

Why is Synopsys stock sliding today?

Synopsys (SNPS) stock fell 2.0% to $456.73 after Anthropic's IPO roadshow highlighted AI-driven chip design, raising competition concerns. The stock has declined further from its 52-week high of $539.48, with One Way Holdings LLC reducing its position by 99%. Investors are evaluating Synopsys's valuation and integration risks amid broader market uncertainty.

$SNPSMed

Why Should You Think About Synopsys Differently Now?

Synopsys (SNPS) trades at 80.8x P/E, focusing on AI-driven chip design and Ansys. Its IP business, which underperformed due to export restrictions and customer challenges, returned to growth in Q3 2026. Ansys revenue was 1.5x Design IP's revenue in the same quarter. Management highlights a shift to a licensing-plus-royalties model, with a $1B+ deal with Amazon.

$SNPSMed

S&P lifts Synopsys to ’BBB+’ as chip-design leader capitalizes on AI demand

S&P Global Ratings upgraded Synopsys Inc's credit rating to 'BBB+' from 'BBB', citing strong long-term growth prospects driven by AI demand. The company expects mid-teens revenue growth through 2029 and improved profitability, with 2029 EBITDA margin projected at 49%. Synopsys is also accelerating cost synergies from its Ansys acquisition and expanding commercial traction, including a $1B+ contract with Amazon.

$AMZNMedAI 8/10

Amazon and Synopsys seal $1bn technology partnership

Amazon and Synopsys have signed a $1 billion deal to accelerate Amazon's custom silicon innovation and advance AI products and cloud infrastructure. The multi-year agreement builds on 15 years of collaboration, with Synopsys providing application-optimized silicon IP. Amazon's Peter DeSantis highlighted the impact of custom silicon on AWS, while Synopsys' Sassine Ghazi emphasized the partnership's role in shaping AI-native engineering.